Thermo Fisher wins FDA approval for next-generation sequencing companion diagnostic tied to new HER2-mutant NSCLC therapy

Thermo Fisher Scientific (NYSE: TMO) has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic for Boehringer Ingelheim’s HERNEXEOS (zongertinib tablets), marking a significant step forward in precision oncology for patients with a rare form of non-small cell lung cancer (NSCLC). The decision enables clinicians and pathologists to detect tumors with human epidermal growth factor receptor 2 (HER2/ERBB2) tyrosine kinase domain (TKD) activating mutations, guiding treatment with the first and only orally administered targeted therapy for this mutation subtype.

The FDA granted accelerated approval to HERNEXEOS on August 8, 2025, for adult patients with unresectable or metastatic non-squamous NSCLC harboring HER2 TKD mutations who have received prior systemic therapy. Approval was based on objective response rate and duration of response data, with continued authorization contingent upon confirmatory trials demonstrating clinical benefit. Accelerated approval in oncology has become a critical pathway for addressing high unmet medical needs in rare molecular subsets, allowing earlier access to promising treatments while definitive data is still being gathered.

How does the FDA approval strengthen Thermo Fisher’s position in the global companion diagnostics market?

This latest FDA clearance reinforces Thermo Fisher Scientific’s standing in the next-generation sequencing (NGS) companion diagnostics segment. The Oncomine Dx Target Test, first approved by the FDA in 2017, represented one of the earliest examples of a comprehensive NGS-based test gaining regulatory acceptance for clinical use. Initially indicated for identifying EGFR mutations, ALK rearrangements, and ROS1 fusions in NSCLC, the platform has evolved to detect an expanding panel of biomarkers across multiple tumor types.

Today, the Oncomine Dx Target Test has gained regulatory clearance in 20 countries for 11 biomarkers linked to more than 20 targeted therapies. The test’s reimbursement coverage spans the United States, Europe, Japan, South Korea, and Israel, extending to over 550 million lives. This global access footprint is a key commercial differentiator, allowing pharmaceutical partners to align drug launches with a pre-validated, globally available diagnostic platform.

In the United States, the test supports targeted therapy selection for multiple cancers beyond NSCLC, including cholangiocarcinoma, astrocytoma, oligodendroglioma, anaplastic thyroid cancer, medullary thyroid cancer, and differentiated thyroid cancer. For healthcare providers, using a single, FDA-approved platform for multiple indications reduces workflow complexity and can help laboratories maximize return on investment in sequencing infrastructure.

Why is identifying HER2 mutations in NSCLC patients both clinically and commercially important?

Lung cancer remains the second most common cancer among men and women in the United States, with NSCLC comprising 85–90% of all cases. HER2 mutations are relatively rare, occurring in approximately 2–4% of NSCLC patients, but they are associated with more aggressive disease biology and worse prognosis compared to other driver mutations such as EGFR or ALK.

Historically, treatment options for HER2-mutant NSCLC were limited, often involving non-targeted chemotherapy or off-label use of HER2-targeting agents developed for breast cancer. These approaches produced modest response rates and limited durability. The approval of HERNEXEOS, an orally administered tyrosine kinase inhibitor (TKI), provides a dedicated, mutation-specific therapy that can be taken at home, potentially improving patient adherence and quality of life.

From a commercial standpoint, rare mutation-driven markets—sometimes referred to as “precision oncology micro-segments”—can be highly lucrative. Targeted therapies for rare mutations often command premium pricing and face less generic competition, while companion diagnostics enable efficient identification of eligible patients, reducing unnecessary drug exposure and associated costs for payers.

How does the collaboration with Thermo Fisher align with Boehringer Ingelheim’s oncology strategy?

Boehringer Ingelheim has built its oncology strategy around molecularly targeted treatments that address defined subsets of patients, aiming to deliver higher clinical value in areas where existing therapies are inadequate. The launch of HERNEXEOS fits this approach, focusing on a genetically defined patient group with clear unmet needs.

Partnering with Thermo Fisher allows Boehringer to integrate patient identification seamlessly into the treatment pathway. By leveraging a widely used, FDA-approved diagnostic platform, the company eliminates the delays that can occur when new drugs require novel or proprietary testing methods. This integration not only accelerates time to treatment but also increases the likelihood of physician adoption, particularly in community oncology settings where access to advanced molecular testing can be limited.

What does institutional sentiment suggest about the long-term outlook for NGS-based companion diagnostics?

Institutional sentiment toward NGS-based companion diagnostics is strongly positive, especially for platforms that are multi-indication and scalable. From an investment perspective, the recurring revenue model associated with ongoing test utilization across multiple drugs and cancer types provides stability in an otherwise volatile diagnostics market.

Thermo Fisher’s platform is well positioned to capture a growing share of this market. Analysts tracking the space note that the FDA’s increasing willingness to approve diagnostics and drugs concurrently—particularly for rare mutations—reduces commercialization risk for pharmaceutical partners. This co-development model is expected to remain a cornerstone of precision oncology, as it aligns incentives between diagnostics companies and drugmakers.

How could this approval shape precision oncology adoption and patient care pathways over the next decade?

Advances in NGS technology are accelerating the shift toward biomarker-driven cancer care. Thermo Fisher recently introduced a rapid sequencing solution capable of delivering results in as little as 24 hours, a development that could have profound implications for treatment timelines in aggressive cancers like HER2-mutant NSCLC.

For healthcare providers, shorter turnaround times can enable earlier initiation of effective therapy, while payers benefit from reduced costs associated with ineffective treatments. Over the next decade, multi-biomarker NGS panels are expected to become standard at diagnosis for most advanced cancers, replacing sequential single-biomarker testing.

The approval of the Oncomine Dx Target Test for HERNEXEOS not only provides immediate clinical benefit but also reinforces a broader trend toward integrated diagnostic-drug launches. As more targeted therapies enter the market, and as tumor profiling becomes standard practice, the role of companion diagnostics will expand further—potentially encompassing minimal residual disease monitoring, treatment resistance detection, and longitudinal disease tracking.

How could the combined drug and diagnostic launch impact oncology treatment adoption and market growth over the next decade?

For Thermo Fisher Scientific, this approval strengthens its reputation as a global leader in companion diagnostics, positioning it to secure additional partnerships with pharmaceutical companies developing targeted therapies. For Boehringer Ingelheim, the integration of an FDA-approved, widely available diagnostic reduces barriers to adoption for HERNEXEOS and enhances its competitive positioning in the precision oncology market.

The broader oncology ecosystem stands to benefit as well. Patients gain access to a targeted treatment option for a mutation that has historically been underserved, clinicians gain a reliable and accessible tool for identifying eligible patients, and payers can more effectively allocate resources toward treatments with a higher likelihood of success.